DYAI Stock Analysis: Buy, Sell, or Hold?
DYAI - Dyadic International, Inc.
$1.06
0.01 (0.95%)
▲
5d:
-6.19%
30d:
+12.71%
90d:
+34.18%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 12, 2026
7d
Get Alerted When DYAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DYAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DYAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: DYAI is currently trading at $1.06, which is considered fair relative to its 30-day fair value range of $0.95 to $1.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 31.8) compared to its historical average (47.7). Remarkably, the market is currently pricing in an annual earnings decline of 12.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DYAI is in a uptrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+466.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DYAI is in a uptrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+466.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.95 -
$1.23
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 466.0% below Wall St target ($6.00)
- CAUTION: Recommendation downgraded due to -6.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.95 -
$1.23
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.03
Resistance Level
$1.60
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.83
Wall Street Target
$6.00
(+466.0%)
Revenue Growth (YoY)
182.3%
Profit Margin
-191.5%
Valuation Discount vs History
-12.6% cheaper
PE vs Historical
31.8 vs 47.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.6%
(market-implied from PE analysis)
1-Year Target
$0.95
(-10%)
2-Year Target
$0.86
(-19%)
3-Year Target
$0.77
(-27%)
3-Yr Target (if PE normalizes)
(PE: 32→48)
$1.16
(+9%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 31.8 to 47.7
Stabilization Target:
$1.59
(+49.9%)
PE Expansion Potential:
+49.9%
Share & Embed Analysis
Last updated: August 04, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
